Adding stress biomarkers to high-sensitivity cardiac troponin for rapid non-ST-elevation myocardial infarction rule-out protocols
暂无分享,去创建一个
P. Collinson | T. Omland | J. Boeddinghaus | T. Nestelberger | C. Mueller | K. Vikenes | L. Koechlin | Ø. Skadberg | A. Larsen | K. Aakre | J. Langørgen | R. Bjørneklett | P. Lopez‐Ayala | O. Steiro | A. Sanchez | H. Strand | V. Bonarjee | Ø. Mjelva | H. L. Tjora | I. Restan | Ø. R. Mjelva | C. Mueller | A. Y. Sanchez | Øistein R. Mjelva
[1] Ò. Miró,et al. Cardiovascular Biomarkers in the Early Discrimination of Type 2 Myocardial Infarction. , 2021, JAMA cardiology.
[2] S. Blankenberg,et al. Critical appraisal of the 2020 ESC guideline recommendations on diagnosis and risk assessment in patients with suspected non-ST-segment elevation acute coronary syndrome , 2021, Clinical Research in Cardiology.
[3] H. Bundgaard,et al. Temporal Release of High-Sensitivity Cardiac Troponin T and I and Copeptin After Brief Induced Coronary Artery Balloon Occlusion in Humans. , 2020, Circulation.
[4] Deepak L. Bhatt,et al. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. , 2020, European heart journal.
[5] Ò. Miró,et al. Early Diagnosis of Myocardial Infarction With Point-of-Care High-Sensitivity Cardiac Troponin I. , 2020, Journal of the American College of Cardiology.
[6] S. Satar,et al. Does stress hyperglycemia affect mortality? Acute myocardial infarction – case control study , 2019, Archives of medical sciences. Atherosclerotic diseases.
[7] A. Jaffe,et al. Copeptin to rule out myocardial infarction in Blacks versus Caucasians , 2019, European heart journal. Acute cardiovascular care.
[8] R. Bingisser,et al. Outcome of Applying the ESC 0/1-hour Algorithm in Patients With Suspected Myocardial Infarction. , 2019, Journal of the American College of Cardiology.
[9] P. Collinson,et al. Aiming toWards Evidence baSed inTerpretation of Cardiac biOmarkers in patients pResenting with chest pain-the WESTCOR study: study design , 2019, Scandinavian cardiovascular journal : SCJ.
[10] A. von Eckardstein,et al. Comparison of fourteen rule-out strategies for acute myocardial infarction. , 2019, International journal of cardiology.
[11] R. Body,et al. Combined testing of copeptin and high-sensitivity cardiac troponin T at presentation in comparison to other algorithms for rapid rule-out of acute myocardial infarction. , 2019, International journal of cardiology.
[12] Jostein Dale,et al. Description of chest pain patients in a Norwegian emergency department , 2019, Scandinavian cardiovascular journal : SCJ.
[13] Jeroen J. Bax,et al. Fourth Universal Definition of Myocardial Infarction (2018). , 2018, Circulation.
[14] Kristian Thygesen,et al. Fourth Universal Definition of Myocardial Infarction (2018). , 2018, Journal of the American College of Cardiology.
[15] S. Hadjadj,et al. Plasma copeptin, kidney disease, and risk for cardiovascular morbidity and mortality in two cohorts of type 2 diabetes , 2018, Cardiovascular Diabetology.
[16] Ò. Miró,et al. Prospective Validation of the 0/1-h Algorithm for Early Diagnosis of Myocardial Infarction. , 2018, Journal of the American College of Cardiology.
[17] Ò. Miró,et al. Direct Comparison of 4 Very Early Rule-Out Strategies for Acute Myocardial Infarction Using High-Sensitivity Cardiac Troponin I , 2017, Circulation.
[18] P. Collinson,et al. How Well Do Laboratories Adhere to Recommended Clinical Guidelines for the Management of Myocardial Infarction: The CARdiac MArker Guidelines Uptake in Europe Study (CARMAGUE). , 2016, Clinical chemistry.
[19] A. Lassen,et al. Diagnostic packages can be assigned accurately in emergency departments. A multi-centre cohort study. , 2016, Danish medical journal.
[20] A. Schoenenberger,et al. Incremental value of copeptin in suspected acute myocardial infarction very early after symptom onset , 2016, European heart journal. Acute cardiovascular care.
[21] S. Fichtlscherer,et al. Analyzing the Release of Copeptin from the Heart in Acute Myocardial Infarction Using a Transcoronary Gradient Model , 2016, Scientific Reports.
[22] P. Collinson,et al. High-sensitivity cardiac troponin I at presentation in patients with suspected acute coronary syndrome: a cohort study , 2015, The Lancet.
[23] C. Vilaplana,et al. Use of copeptin and high-sensitive cardiac troponin T for diagnosis and prognosis in patients with diabetes mellitus and suspected acute myocardial infarction. , 2015, International journal of cardiology.
[24] J. Greenslade,et al. Combining presentation high-sensitivity cardiac troponin I and glucose measurements to rule-out an acute myocardial infarction in patients presenting to emergency department with chest pain. , 2015, Clinical biochemistry.
[25] M. Sebbane,et al. A systematic review and collaborative meta-analysis to determine the incremental value of copeptin for rapid rule-out of acute myocardial infarction. , 2014, The American journal of cardiology.
[26] S. Blankenberg,et al. Early discharge using single cardiac troponin and copeptin testing in patients with suspected acute coronary syndrome (ACS): a randomized, controlled clinical process study , 2014, European heart journal.
[27] P. Collinson,et al. Diagnostic accuracy of combined cardiac troponin and copeptin assessment for early rule-out of myocardial infarction: a systematic review and meta-analysis , 2014, European heart journal. Acute cardiovascular care.
[28] A. Kosinski. A weighted generalized score statistic for comparison of predictive values of diagnostic tests , 2013, Statistics in medicine.
[29] R. Niska,et al. National Hospital Ambulatory Medical Care Survey: 2007 emergency department summary. , 2010, National health statistics reports.
[30] N. Morgenthaler,et al. Copeptin: a biomarker of cardiovascular and renal function. , 2010, Congestive heart failure.
[31] Tobias Reichlin,et al. Early diagnosis of myocardial infarction with sensitive cardiac troponin assays. , 2009, The New England journal of medicine.
[32] E. DeLong,et al. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. , 1988, Biometrics.
[33] A. Anand,et al. High-Sensitivity Cardiac Troponin on Presentation to Rule Out Myocardial Infarction A Stepped-Wedge Cluster Randomized Controlled Trial , 2021 .
[34] S. Mehta,et al. Rule-In and Rule-Out of Myocardial Infarction Using Cardiac Troponin and Glycemic Biomarkers in Patients with Symptoms Suggestive of Acute Coronary Syndrome. , 2017, Clinical chemistry.
[35] Jeroen J. Bax,et al. [2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC)]. , 2016, Giornale italiano di cardiologia.
[36] J. Alpert,et al. The third universal definition of myocardial infarction , 2013 .
[37] Jeroen J. Bax,et al. Third universal definition of myocardial infarction. , 2012, Circulation.
[38] Michael Marber,et al. Sensitive troponin I assay in early diagnosis of acute myocardial infarction , 2010 .